Cytokine arrays revealed that the three genes mentioned above were down-regulated at the mRNA and protein levels in IDH1-mutated tumors, suggesting that immune infiltration and chemotaxis are regulated by IDH1 mutations and that a reduced aggressive part of the tumor-associated immune system could provide IDH-mutant glioma patients with a longer survival duration (12). This evidence concerns the gene IDH2 and glioma.